Study to Validate a Blood Test for Early Detection of Pancreatic Ductal Adenocarcinoma

What this Trial Is About

Pancreatic ductal adenocarcinoma PDAC is a highly deadly cancer often diagnosed at late stages, limiting treatment options. This research evaluates a new noninvasive method to detect PDAC early by analyzing specific microRNAs miRNAs found in circulating exosomes and blood serum. The study will validate a previously identified signature of 13 miRNAs to improve early detection accuracy in a larger international group. The study uses a diagnostic test called PANXEON, which measures the levels of 5 cell-free and 8 exosome-derived miRNAs from blood plasma samples. Participants include individuals diagnosed with PDAC and those without the disease for comparison. The study will observe these groups prospectively to assess the tests ability to detect PDAC at early stages. Participants will provide plasma samples for miRNA analysis without receiving treatment as part of the study. Researchers will measure the tests sensitivity, specificity, and accuracy over about one year. The study includes adults aged 18 and older and allows healthy volunteers without pancreatic cancer. It aims to improve early detection tools for PDAC over the study period ending in 2030.

Pancreatic Cancer Detection Consortium